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ABSTRACT
Objective: The Herpes Outbreak Impact Questionnaire (HOIQ) and
Herpes Symptom Checklist (HSC) are patient-completed questionnaires
for assessing genital herpes outbreaks. This report describes the validation
of paper-and-pencil versions of the scales and responsiveness assessments
in an Australian clinical trial.
Methods: Acceptability of the language of the original UK versions was
tested with Australians. The HOIQ and HSC were then ﬁeld-tested with
patients. The new versions were validated using patients’ daily responses
to the questionnaires in a famciclovir study.
Results: The HOIQ and HSC were readily adapted into Australian
English and were acceptable to patients. Psychometric sample: N = 151;
81 (54%) male; mean age 39.9  11.6 years; mean outbreaks 5.1  3.0
per year. Internal consistency was good (alphas at outbreak 1 ranged
0.84–0.90 HOIQ and 0.73–0.87 HSC). Rasch analysis showed item sta-
bility over time. Correlations between HOIQ and HSC ranged from 0.46
to 0.60. Both scales distinguished outbreak healing presence or absence at
day 6 (P = 0.001), and the HOIQ scale distinguished between symptom
severity groups (P < 0.001). Scale scores declined signiﬁcantly over study
duration, exhibiting large effect sizes.
Conclusions: The paper-and-pencil HOIQ and HSC were reliable, valid,
and responsive in a clinical trial setting. These instruments are recom-
mended for use in clinical studies.
Keywords: functioning, genital herpes, HOIQ, HSC, patient-reported out-
comes, responsiveness, symptoms.
Introduction
High herpes simplex virus prevalence rates have been reported in
many developed countries [1], with genital herpes as one of the
most common sexually transmitted infections. Although genital
herpes is frequently asymptomatic, for those who experience
symptoms, outbreaks can be painful and debilitating [2]. Recur-
rent outbreaks are characterized by itching, pain, general ﬂu-like
symptoms, and vesicular and ulcerative lesions taking up to 6
days to heal [3]. Additionally, outbreaks can have a signiﬁcant
detrimental psychosocial impact [4].
Psychosocial and quality of life (QoL) impact in recurrent
genital herpes (RGH) has been well documented using disease-
speciﬁc instruments such as the RGHQoL Questionnaire [5].
However, limited information is available on the impact of
herpes during an outbreak. The Herpes Outbreak Impact Ques-
tionnaire (HOIQ) and the Herpes Symptom Checklist (HSC)
were developed to address this need [6].
The HOIQ is a 12-item patient-completed questionnaire
assessing the daily impact of herpes outbreaks on the individual’s
emotional, self-care, social, sexual, and work-related function-
ing. Patients rate the impact on a 4-point scale. Total scores range
from 0 to 36, in increasing impact on function. The HSC is a
13-item checklist of herpes symptoms, where respondents record
the severity of symptoms (tingling, pain, itching, tiredness, etc.)
daily on a 4-point scale. Total scores range from 0 to 39, in
increasing severity.
Although the scales have been shown to be internally consis-
tent (Cronbach’s alpha: HSC = 0.83; HOIQ = 0.87) and to ﬁt the
Rasch model, they were validated via computer administration.
The objective of the present study was to provide additional
validation of the HOIQ and HSC (via paper-and-pencil admin-
istration) and to assess their responsiveness within a clinical trial.
Methods
As the trial was conducted in Australia, it was ﬁrst necessary to
ensure that the UK version of the scales were acceptable to
Australians.
Translation
The objective of the “translation” was to produce a conceptually
equivalent version for Australians, expressed in everyday lan-
guage. This was produced using a lay panel of Australians of
average or below-average educational level and who did not have
a diagnosis of RGH.
Field Test
Field-test interviews were conducted with Australian patients
with RGH to assess the relevance, acceptability, comprehensive-
ness, and clarity of the questionnaire items.
Psychometric Evaluation
Data from a study comparing a 2-day versus 5-day regimen of
famciclovir were used to validate the new versions of the mea-
sures. Study participants completed the HOIQ and HSC (paper-
and-pencil versions) daily for 6 days during two consecutive
genital herpes outbreaks. Inclusion criteria for the famciclovir
study were: age  18 years; a clinical diagnosis of genital herpes;
and at least two genital herpes outbreaks within the last 12
months, or one outbreak in the last 6 months, or within 6 months
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following an initial episode. Exclusion criteria were: taking sup-
pressive antiviral therapy, pregnancy, breast-feeding, or planning
a pregnancy during the study.
Internal consistency was assessed using Cronbach’s alpha.
Reproducibility was determined by assessing the stability of the
items over time using Rasch analysis [7]. Rasch analysis enables
the assessment of differential item functioning (DIF) within the
Rasch Unidimensional Measurement Model software frame-
work, with signiﬁcant DIF taken to indicate item instability.
Convergent validity was assessed by correlating scores on the
HOIQ with those on the HSC using Spearman rank correlations.
Moderate associations were expected as they measure similar but
distinct constructs (impairment and disability).
Discriminative validity was assessed by comparing scores of
those whose outbreak had or had not healed according to a
physician’s assessment on day 6. Scores on the HOIQ were also
examined between individuals who differed according to the
level of symptoms they experienced as measured by the HSC.
Severity groups were created by using quartile scores on the
HSC: 0 to 2, mild symptoms; 3 to 6, moderate symptoms; 7 to
11, quite severe symptoms; 12+, very severe symptoms.
Differences between the groups were tested by Mann–
Whitney U tests or Kruskal–Wallis analyses of variance.
Responsiveness was assessed by effect size thresholds (0.2–
0.5 = small change; 0.5–0.8 = moderate change; >0.8 = large
change) proposed by Cohen [8] and by the signiﬁcance of
changes in scores from day 1 to day 6 using Wilcoxon signed-
rank tests.
Preliminary estimates of the minimal important differences
(MIDs) for the scales were derived using distribution-based
methods. Scores needed to achieve effect sizes, and the standard
error of measurement (SEM) were calculated. Change score
needed to achieve a 0.50 effect size (or half a standard deviation)
[9], and the SEM [10] have both been suggested as suitable MID
estimates.
Results
Translation
The lay panel was comfortable with the HOIQ and HSC wording
but changed some words not commonly used in Australia.
Eighteen patients (55.6% male) with RGH, aged 25 to 69
years, participated in ﬁeld-test interviews. All respondents
thought the scales were easily understood and relevant to their
experience of genital herpes, although minor changes in wording
were adopted. The mean time required to complete the two
measures was less than 4 minutes.
Validation
Data from 151 (54% male, mean age 39.9  11.6 years; mean
outbreaks per year 5.1  3.0) people were available for the
validation and responsiveness analyses (Table 1).
Table 2 shows the range of Cronbach’s alpha coefﬁcients for
the HOIQ and HSC (over the 6 days in each outbreak). Both
instruments had adequate internal consistency (>0.70); however,
the alpha coefﬁcient for the HSC score on day 6 at outbreak 2
was lower—probably because of the low scores, as most out-
breaks had healed by this time and reduced sample size on the
last day.
No DIF (P > 0.01) by time was found for the HOIQ between
day 1 and day 3 scores at outbreak 1 or between day 1 scores of
outbreaks 1 and 2. For the same assessment, only one item in the
HSC exhibited DIF over time on each occasion. This would
not compromise the reproducibility of the HSC. The results
provide evidence that the HOIQ and HSC have item stability
over time.
A Spearman correlation coefﬁcient matrix was created
between HOIQ and HSC scores for each day during outbreak 1.
Over the 6 days, the correlations ranged from 0.46 to 0.60,
indicating that they aremeasuring related, but distinct, constructs.
Those who had experienced the condition longer (>sample
median time since diagnosis) had fewer symptoms (HSC
P = 0.02) and better functioning (HOIQ P = 0.049) at day 6.
There were no clear patterns between the number of outbreaks
per year and HOIQ or HSC scores.
Individuals whose outbreak had healed by day 6 scored sub-
stantially lower on the HOIQ and HSC (P = 0.001) than those
whose outbreak had not healed (Fig. 1), providing evidence of
the discriminative power of both measures.
The difference in HOIQ scores by symptom group was highly
signiﬁcant (P < 0.001; Fig. 2), conﬁrming that respondents with
the most severe symptoms experience the greatest functional
limitations.
HOIQ and HSC scores decreased signiﬁcantly (for both out-
breaks) between day 1 and day 6, supporting the responsiveness
of the scales (Fig. 3). Effect sizes for the HOIQ and HSC, based
on the difference between day 1 and day 6 assessments for both
outbreaks, are shown in Table 2. Cohen’s effect size thresholds
show that a large change has occurred within both measures in
both outbreaks over the complete assessment period, providing
further evidence of the responsiveness of these measures.
Distributional estimates of the MIDs (Table 2) suggest a
change of between 2 and 2.5 on each scale could be considered
important.
Conclusions
Using a lay panel and ﬁeld tests with relevant patients, new
versions of the HOIQ and HSC were created for Australia that
were conceptually equivalent to the original UK versions.
Psychometric analyses showed that both measures had
adequate internal consistency and that HOIQ and HSC exhibit
moderate correlations with each other. Both the HOIQ and
HSC exhibit little DIF by time, indicating that responses are
not signiﬁcantly inﬂuenced by time and providing evidence of
item stability.
Both patient-completed instruments could discriminate out-
break healing in individuals (according to physician assessment)
Table 1 Sample for psychometric evaluation
N = 151 No. %
Sex
Male 81 53.6
Female 70 46.4
Age (years)
Mean (SD) 39.9 (11.6)
Range 20–73
Number of outbreaks per year
Mean (SD) 5.1 (3.0)
Range 1–12
Time since ﬁrst-ever outbreak (years)
Mean (SD) 8.2 (7.8)
Range 0–34
Time between study outbreaks 1 and 2 (days)
Mean (SD) 50.8 (47.7)
Range 7–209
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at their last assessment, providing evidence of construct validity.
HOIQ scores differed signiﬁcantly between symptom severity
groups and both scales provided evidence that the impact and
severity of herpes outbreaks decrease over time.
A limitation of the study is that, in the absence of suitable
RGH outbreak measures, the HOIQ and HSC were correlated
with each other. This technique can only provide limited evi-
dence of the validity of either, and in the future, correlational
analyses between these and other questionnaires should be
conducted. In addition, despite the distributional statistics pro-
duced here, further research is required to determine threshold
change scores on the questionnaires that could be used to
denote an important improvement or a responder.
The psychometric analyses gave promising results in terms
of the reliability, validity, and responsiveness of the HOIQ and
HSC when administered via paper-and-pencil mode. The vali-
dation analyses in this study revealed results similar, in terms of
alpha and correlations between the HOIQ and HSC, to those
found in the original validation [6]. Although further research
with these scales is encouraged, both can be considered sui-
table for inclusion in clinical trials and for use in clinical
practice.
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Table 2 HOIQ and HSC internal consistency, effect sizes, and distributional minimal important difference
Scale
Alpha range
(day 1–day 6) Effect sizes
Standard error
of measurement
Change score to
achieve effect size
Outbreak 1 Outbreak 2 Outbreak 1 Outbreak 2 Outbreak 1 Outbreak 2 0.4 0.5
HOIQ 0.90–0.84 0.88–0.81 0.85 0.92 2.32 2.22 2.40 3.0
HSC 0.87–0.73 0.80–0.64 1.13 1.44 2.29 2.33 1.76 2.20
HOIQ, Herpes Outbreak Impact Questionnaire; HSC, Herpes Symptom Checklist.
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Figure 1 Scores according to whether healing had occurred at day 6. HOIQ,
Herpes Outbreak Impact Questionnaire; HSC, Herpes Symptom Checklist.
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Figure 2 Mean Herpes Outbreak Impact Questionnaire (HOIQ) scores by
symptom severity.
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Figure 3 Change in Herpes Outbreak Impact Questionnaire (HOIQ) and
Herpes Symptom Checklist (HSC) mean scores over time.
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